Opinion|Videos|January 29, 2025
Best Practices in Switching PBC Therapies
Panelists discuss how clinicians may transition patients to newer agents due to factors such as inadequate biochemical response, tolerability issues (particularly pruritus), or patient preference, while carefully considering the need for washout periods based on each drug's pharmacokinetics and mechanism of action.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are some reasons why clinicians may consider a transition from obeticholic acid to seladelpar or elafibranor for PBC?
- Given the different mechanisms of action of obeticholic acid, seladelpar, and elafibranor, what factors should be considered in determining the need for a washout period between treatments vs direct transition?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Trump Executive Order Recommends Separating MMR Into 3 Shots
2
The Inflation Reduction Act and Oncology Drug Pricing: What Pharmacists Need to Know
3
FDA Fast Tracks First-in-Class TNFR2 Antibody as Chemotherapy-Free Strategy for Platinum-Resistant Ovarian Cancer
4
Beat the Heat: 10 Common Medication Culprits Causing Heat Intolerance
5